Jonathan Brett Orens, M.D.

Headshot of Jonathan Brett Orens
  • Interim Director, Division of Pulmonary & Critical Care Medicine
  • Professor of Medicine
Male

Expertise

Lung Transplant, Pulmonary and Critical Care Medicine ...read more

Research Interests

Clinical outcomes of lung transplantation; Chronic allograft rejection; Ischemic reperfusion injury ("primary graft dysfunction") ...read more

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment

Locations

The Johns Hopkins Hospital

Appointment Phone: 410-550-5864
1830 E. Monument Street
1830 Building 5th Floor Pulmonary
Baltimore, MD 21287
Phone: 410-955-3467
The Johns Hopkins Hospital - Google Maps

Johns Hopkins Bayview Medical Center

Appointment Phone: 410-550-5864
4940 Eastern Avenue
Baltimore, MD 21224
Phone: 410-550-5633
Johns Hopkins Bayview Medical Center - Google Maps

Background

Dr. Jonathan Orens is a professor of medicine at the Johns Hopkins University School of Medicine. His areas of clinical expertise include pulmonary and critical care medicine. He is an internationally recognized expert in lung transplantation.

Dr. Orens received his M.D. from the University of Maryland School of Medicine. He completed his residency at the University of Maryland Medical Center and performed a fellowship in pulmonary and critical care medicine at the University of Michigan Hospitals. Dr. Orens joined the Johns Hopkins faculty in 1998.

His research interests include clinical outcomes of lung transplantation, chronic allograft rejection and ischemic reperfusion injury.

...read more

Titles

  • Interim Director, Division of Pulmonary & Critical Care Medicine
  • Professor of Medicine

Departments / Divisions

Centers & Institutes

Education

Degrees

  • MD; University of Maryland School of Medicine (1987)

Residencies

  • Internal Medicine; University of Maryland Medical Center (1991)

Fellowships

  • Pulmonary and Critical Care Medicine; University of Michigan Health System (1994)

Additional Training

  • National Board of Physicians and Surgeons - Internal Medicine, Pulmonary Disease, and Critical Care Medicine (expires: 02/29/2024)

Research & Publications

Research Summary

Dr. Orens’ research interests are focused on lung transplantation. He is particularly interested in lung transplant outcomes specifically assessing risk factors for the development of chronic allograft rejection and primary graft dysfunction and developing new treatment strategies for these problems. Dr. Orens is internationally recognized as an expert in the care and management of lung transplant recipients.  He was the first to discover the benefit of treating lung allograft dysfunction with the macrolide antibiotic Azithromycin which is now a standard of care in lung transplantation.  He was the first author of the 2006 International Guidelines for the Selection of Lung Transplant Candidates.  He currently participates in several lung transplant research consortia including the NIH-sponsored Lung Transplant Outcomes Group, the NIH Genomic Research Alliance for Transplant, and an NIH-sponsored Clinical Trials in Organ Transplant program.

Clinical Trials

Genome Transplant Dynamics

Selected Publications

Shah RJ, Wickersham N, Lederer DJ, Palmer SM, Cantu E, Diamond JM, Kawut SM, Lama VN, Bhorade S, Crespo M, Demissie E, Sonett J, Wille K, Orens J, Weinacker A, Shah P, Arcasoy S, Wilkes DS, Christie JD, Ware LB; Lung Transplant Outcomes Group. “Preoperative plasma club (clara) cell secretory protein levels are associated with primary graft dysfunction after lung transplantation.” Am J Transplant. 2014 Feb;14(2):446-52. doi: 10.1111/ajt.12541. Epub 2014 Jan 8. 

Diamond JM, Akimova T, Kazi A, Shah RJ, Cantu E, Feng R, Levine MH, Kawut SM, Meyer NJ, Lee JC, Hancock WW, Aplenc R, Ware LB, Palmer SM, Bhorade S, Lama VN, Weinacker A, Orens J, Wille K, Crespo M, Lederer DJ, Arcasoy S, Demissie E, Christie JD; for the Lung Transplant Outcomes Group. “Genetic variation in prostaglandin E2 pathway is associated with primary graft dysfunction.” Am J Respir Crit Care Med. 2014 Jan 27. [Epub ahead of print].

Eberlein M, Reed RM, Maidaa M, Bolukbas S, Arnaoutakis GJ, Orens JB, Brower RG, Merlo CA, Hunsicker LG. “Donor-recipient size matching and survival after lung transplantation: A cohort study.” Ann Am Thorac Soc. 2013 Oct;10(5):418-25. doi: 10.1513/AnnalsATS.201301-008OC.

Miller HL, Shah PD, Orens JB, McDyer JF. “Prevention of airway allograft tolerance by polyinosinic: Polycytidylic acid requires type I interferon responsiveness for mouse airway obliteration.” J Heart Lung Transplant. 2013 Sep;32(9):914-24. doi: 10.1016/j.healun.2013.06.017.

Shah P, Orens JB. “Impact of nutritional state on lung transplant outcomes: The weight of the evidence.” J Heart Lung Transplant. 2013 Aug;32(8):755-6. doi: 10.1016/j.healun.2013.06.001.

Eberlein M, Reed RM, Bolukbas S, Parekh KR, Arnaoutakis GJ, Orens JB, Brower RG, Shah AS, Hunsicker L, Merlo CA. “Lung size mismatch and survival after single and bilateral lung transplantation.” Ann Thorac Surg. 2013 Aug;96(2):457-63. doi: 10.1016/j.athoracsur.2013.04.064. Epub 2013 Jun 26.

Shah RJ, Diamond JM, Cantu E, Lee JC, Lederer DJ, Lama VN, Orens J, Weinacker A, Wilkes DS, Bhorade S, Wille KM, Ware LB, Palmer SM, Crespo M, Localio AR, Demissie E, Kawut SM, Bellamy SL, Christie JD. “Latent class analysis identifies distinct phenotypes of primary graft dysfunction after lung transplantation.” Chest. 2013 Aug;144(2):616-22. doi: 10.1378/chest.12-1480.

Yarmus L, Akulian J, Gilbert C, Illei P, Shah P, Merlo C, Orens J, Feller-Kopman D. “Cryoprobe transbronchial lung biopsy in patients after lung transplantation: A pilot safety study.” Chest. 2013 Mar;143(3):621-6.

Diamond JM, Lee JC, Kawut SM, Shah RJ, Localio AR, Bellamy SL, Lederer DJ, Cantu E, Kohl BA, Lama VN, Bhorade SM, Crespo M, Demissie E, Sonett J, Wille K, Orens J, Shah AS, Weinacker A, Arcasoy S, Shah PD, Wilkes DS, Ware LB, Palmer SM, Christie JD; Lung Transplant Outcomes Group. “Clinical risk factors for primary graft dysfunction after lung transplantation.” Am J Respir Crit Care Med. 2013 Mar 1;187(5):527-34. doi: 10.1164/rccm.201210-1865OC. Epub 2013 Jan 10.

Diamond JM, Porteous MK, Cantu E, Meyer NJ, Shah RJ, Lederer DJ, Kawut SM, Lee J, Bellamy SL, Palmer SM, Lama VN, Bhorade SM, Crespo M, Demissie E, Wille K, Orens J, Shah PD, Weinacker A, Weill D, Arcasoy S, Wilkes DS, Ware LB, Christie JD; Lung Transplant Outcomes Group. “Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation.” PLoS One. 2012;7(12):e51932. doi: 10.1371/journal.pone.0051932. Epub 2012 Dec 19.

Activities & Honors

Memberships

  • Committee on the Promotion of the Clinical Program Builder and Innovator, Johns Hopkins School of Medicine, 2011
Is this you? Edit Profile
back to top button